Thrombospondin-1 regulation of latent TGF-β activation: A therapeutic target for fibrotic disease
JE Murphy-Ullrich, MJ Suto - Matrix Biology, 2018 - Elsevier
Transforming growth factor-β (TGF-β) is a central player in fibrotic disease. Clinical trials with
global inhibitors of TGF-β have been disappointing, suggesting that a more targeted …
global inhibitors of TGF-β have been disappointing, suggesting that a more targeted …
Thrombospondin-1 regulation of latent TGF-β activation: A therapeutic target for fibrotic disease
JE Murphy-Ullrich, MJ Suto - Matrix biology: journal of the …, 2018 - pubmed.ncbi.nlm.nih.gov
Transforming growth factor-β (TGF-β) is a central player in fibrotic disease. Clinical trials with
global inhibitors of TGF-β have been disappointing, suggesting that a more targeted …
global inhibitors of TGF-β have been disappointing, suggesting that a more targeted …
Thrombospondin-1 regulation of latent TGF-β activation: A therapeutic target for fibrotic disease.
JE Murphy-Ullrich, MJ Suto - … Journal of the International Society for …, 2017 - europepmc.org
Transforming growth factor-β (TGF-β) is a central player in fibrotic disease. Clinical trials with
global inhibitors of TGF-β have been disappointing, suggesting that a more targeted …
global inhibitors of TGF-β have been disappointing, suggesting that a more targeted …
Thrombospondin-1 regulation of latent TGF-β activation: A therapeutic target for fibrotic disease
JE Murphy-Ullrich, MJ Suto - Matrix Biology, 2018 - oceanrep.geomar.de
Transforming growth factor-β (TGF-β) is a central player in fibrotic disease. Clinical trials with
global inhibitors of TGF-β have been disappointing, suggesting that a more targeted …
global inhibitors of TGF-β have been disappointing, suggesting that a more targeted …
[HTML][HTML] Thrombospondin-1 regulation of latent TGF-β activation: a therapeutic target for fibrotic disease
JE Murphy-Ullrich, MJ Suto - … journal of the International Society for …, 2018 - ncbi.nlm.nih.gov
Transforming growth factor-β (TGF-β) is a central player in fibrotic disease. Clinical trials with
global inhibitors of TGF-β have been disappointing, suggesting that a more targeted …
global inhibitors of TGF-β have been disappointing, suggesting that a more targeted …
[PDF][PDF] Thrombospondin-1 regulation of latent TGF-β activation: A therapeutic target for fibrotic disease
JE Murphy-Ullricha, MJ Sutob - Matrix Biol, 2018 - researchgate.net
Transforming growth factor-β (TGF-β) is a central player in fibrotic disease. Clinical trials with
global inhibitors of TGF-β have been disappointing, suggesting that a more targeted …
global inhibitors of TGF-β have been disappointing, suggesting that a more targeted …
[引用][C] Thrombospondin-1 regulation of latent TGF-β activation: A therapeutic target for fibrotic disease
JE Murphy-Ullrich, MJ Suto - Matrix Biology, 2018 - cir.nii.ac.jp
Thrombospondin-1 regulation of latent TGF-β activation: A therapeutic target for fibrotic disease.
JE Murphy-Ullrich, MJ Suto - … Journal of the International Society for …, 2017 - europepmc.org
Transforming growth factor-β (TGF-β) is a central player in fibrotic disease. Clinical trials with
global inhibitors of TGF-β have been disappointing, suggesting that a more targeted …
global inhibitors of TGF-β have been disappointing, suggesting that a more targeted …
Thrombospondin-1 regulation of latent TGF-β activation: A therapeutic target for fibrotic disease
JE Murphy-Ullrich, MJ Suto - Matrix Biology, 2018 - oceanrep.geomar.de
Transforming growth factor-β (TGF-β) is a central player in fibrotic disease. Clinical trials with
global inhibitors of TGF-β have been disappointing, suggesting that a more targeted …
global inhibitors of TGF-β have been disappointing, suggesting that a more targeted …